Kiniksa Pharmaceuticals, Ltd.
Oncostatin M receptor antigen binding proteins

Last updated:

Abstract:

The invention provides anti-oncostatin M receptor-.beta. (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.

Status:
Grant
Type:

Utility

Filling date:

11 Jul 2017

Issue date:

24 Sep 2019